MAVENIR
26.2.2024 07:31:31 CET | Business Wire | Press release
Mavenir and QCT collaborate with Intel to introduce the QuantaEdge EGX77B-1U short form factor server to support Open RAN deployments.
The QuantaEdge EGX77B-1U is a short depth (300mm), low power consumption, highly expandable Multi-Access Edge Computing server featuring the 4th Gen Intel Xeon Scalable processor with Intel vRAN Boost and expandable memory for centralized and distributed Radio Access Networks that are ORAN, TIP, and NEBS GR63 Level 3 and GR3108 Class 2 compliant for 4G and 5G services. Detailed specifications of the EGX77B-1U can be found at both the Mavenir and QCT booths at Mobile World Congress.
Mavenir has been working with Intel diligently to harness and realise the benefits of Intel 4th Gen Xeon processors with Intel vRAN boost. The close collaboration has yielded extensive optimisations among the DU software, Intel’s processor, and the latest advancements in Intel’s FlexRAN reference software across 4G and 5G. These new capabilities and features will now be available on DU platforms, including QuantaEdge EGX77B-1U.
Mike Yang, President of QCT said, “QCT is pleased to collaborate with leading partners in the wireless ecosystem, like Mavenir and Intel, to enable innovations taking advantage of 5G Open RAN. By providing standards-compliant, cost-effective, and robust open platforms, QCT is committed to accelerating a diversity of innovative applications not only at the data centre but also at the edge.”
“Mavenir and QCT are at the forefront of industry innovation, offering high-performance Open RAN software and DU platforms powered by Intel’s latest vRAN processor with Intel vRAN Boost – the world’s first vRAN processor with fully integrated acceleration,” said Cristina Rodriguez, Vice President and General Manager, Wireless Access Networking Division at Intel. “Our collaboration reflects a shared commitment to providing flexible solutions designed to meet the widely varying form factor, power consumption, and environmental requirements of global markets.”
Pardeep Kohli, Mavenir CEO said, “Mavenir is excited for this strategic collaboration with QCT and Intel. This new optimised high capacity 1U chip-down edge server broadens our portfolio of options and expands our Open RAN solution blueprint while leveraging the complementary strengths of each of our respective companies.”
The companies will continue to collaborate and work to satisfy customer demands for a diversity of leading-edge performance and cost optimised options when it comes to the design, supply and deployment of open 5G network solutions.
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About QCT:
Quanta Cloud Technology (QCT) is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms, and enterprises running public, hybrid, and private clouds.
Product lines include hyperconverged and software-defined data center solutions as well as servers, storage, switches, and integrated racks with an ecosystem of hardware components and software partners. QCT designs, manufactures, integrates, and services its offerings via its own global network. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. https://www.qct.io/
Meet QCT at Mobile World Congress 2024 at Booth #5E21 in Hall 5.
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com.
Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)
To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240225326148/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom